Study S000289

A Randomized,Active-controlled,Open-label Clinical Trial to Evaluate the Effect of GLP-1 Receptor Agonist (Exenatide Injection) in Combination With Metformin Therapy Compared to Premixed Insulin (BIAsp30) in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

ClinicalTrials.gov record

Registration

Registration: NCT03018665
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 200
Start: 2017-02
Primary completion: 2021-12
Lead sponsor: The First Hospital of Jilin University
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Exenatide; DRUG:BIAsp30; DRUG:Metformin
Results posted: FALSE

Registered primary outcomes

Rate of Inducing Diabetes Remission [At the end of 12-week treatment]
Change of Rate of Maintaining Diabetes Remission [3,6,12,24,36 months after 12-week treatment]
Time of Maintaining Diabetes Remission [up to 36 months after 12-week treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.